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Abstract 
Aquated cisplatin was added to half-generation PAMAM dendrimers and the resultant 
complexes were purified by centrifuge. The drug-dendrimer complexes were then 
characterised by 1-D and diffusion 
1
H NMR y and ICP-AES. The amount of drug bound was 
found to increase in proportion with dendrimer size: G3.5, 22 cis-{Pt(NH3)2}molecules per 
dendrimer; G4.5, 37; G5.5, 54; and G6.5, 94, which represent only a fraction of the available 
binding sites on each dendrimer (68, 58, 42 and 37%, respectively). Drug release studies 
showed that some drug remains bound to the dendrimer even after prolonged incubation with 
5’GMP at temperatures of 60 oC for over a week (percentage of drug released 18, 30, 35 and 
63%, respectively). Attachment of the drug was found to decrease the radius of the 
dendrimers. Finally, the effect of the dendrimer on drug cytotoxicity was determined using in 
vitro assays with the A2780, A2780cis and A2780cp ovarian cancer cell lines. The free 
dendrimers display no cytotoxicity whilst the drug-dendrimer complexes showed moderate 
activity. In vivo activity was examined using an A2780 tumour xenograft. Cisplatin, at its 
maximum tolerated dose of 6 mg/kg, reduced tumour size by 33% compared to an untreated 
control group. The G6.5 cisplatin-dendrimer complex was administered at two doses (6 and 8 
mg/kg equivalent of cisplatin).  Both were well tolerated by the mice. The lower dose 
displayed comparable activity to cisplatin with a tumour volume reduction of 32%, but the 
higher dose was significantly more active than free cisplatin with a tumour reduction of 45%. 
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1. Introduction 
Cisplatin, cis-diamminedichloridoplatinum(II), has been used for the treatment of human 
cancers for the last 30 years (Fig. 1) [1-2]. Whilst it is highly effective for testicular cancer its 
high dose limiting side-effects and the ability of some cancer types, like ovarian and lung, to 
develop resistance to the drug, greatly limit its use [1].  Five other platinum drugs, 
carboplatin, oxaliplatin, lobaplatin, heptaplatin and nedaplatin are also used in varying 
regions with limited success [1]. Whilst new drugs continue to be developed, they all contain 
structural similarities with cisplatin, and as such exhibit severe dose limiting side-effects [1]. 
As such, over the last decade there has been a shift in focus from drug design to drug delivery 
[1]. 
 
The purpose of a delivery vehicle is to increase the specificity of drug for tumours compared 
with normal cells. For solid tumours, nanosized delivery vehicles can passively target cancers 
through use of the enhanced permeability and retention (EPR) effect. The EPR effect arises 
due to differences between the blood vessels surrounding the tumours and those of normal 
tissues [3]. The blood vessels in tumours are irregular in shape, dilated, leaky or defective and 
the endothelial cells in the vessels are poorly aligned [4]. The defects within the vasculature 
results in blood plasma components such as macromolecules, nano- and lipid particles, 
entering the tumour tissue more effectively [4]. The increased permeability of tumours allows 
the passage of larger molecules into the cells than would normally occur [5]. The enhanced 
permeability can therefore be exploited by nanosized vehicles as these would pass through 
into the tumour but not into healthy tissue, thus increasing the selectivity of these drugs [6]. 
The EPR effect also allows drugs to accumulate in the tumour site due to poor lymphatic 
drainage [5].  
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One family of potential delivery vehicles are dendrimers which are monodispersed polymers, 
spherical in shape and which are be easily functionalised with a range of biologically relevant 
groups (NH2 or COOH), making them ideal for drug delivery applications [7-9]. The number 
of surface groups on a dendrimer is dependent on the number of cascading branches; 
dendrimer sizes are usually expressed in terms of the number of cascades or generations. 
Hence a dendrimer with two cascading branches is a generation 2 (G2) dendrimer [8]. 
Dendrimers with only half a full terminal cascading branch are called half generation (e.g. 
G2.5) dendrimers [8]. Poly(amidoamine) or PAMAM dendrimers consist of polyamide 
branches stemming from a central ammine or diaminoalkane core (see Fig. 1). Full 
generation PAMAM dendrimers have terminal primary amine groups, whilst half generation 
dendrimers have carboxylic acid/carboxylate terminal groups. Full generation PAMAM 
dendrimers have multiple cationic charges in water, making them ideal delivery vehicles for 
anionic drugs (i.e. short interfering RNA or DNA) [10-14], whereas the half generation 
dendrimers have multiple anionic charges which are ideal for cationic drugs or for reversible 
coordination to platinum complexes [15]. PAMAM dendrimers of generations 1 to 10 are 
nanometre in diameter, and thus, ideal for targeting tumours through the EPR effect. 
 
Previously dendrimers have been examined sporadically as delivery vehicles for several 
different types of platinum drugs and complexes [15-22]. These dendrimers have included 
PAMAM, polyglycerol [22], poly(propyleneimine) [23], and thiol-yne derived [21] 
dendrimers with the active components of both cisplatin [17] and oxaliplatin [16] and a novel 
DNA intercalating platinum complex [15]. In some cases the platinum drugs are attached 
non-reversibly to the dendrimer through coordination to the amine groups, but in most cases 
the drugs were attached either by electrostatic attraction [15], or through reversible but direct 
coordination of the platinum atom to the terminal carboxylate groups [16-17]. In one case a 
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G1 poly(propyleneimine) dendrimer was used as the central bridging ligand in a tetranuclear 
platinum complex, instead of as a drug delivery vehicle [23]. Whilst the resultant complex 
was able to bind guanosine, it demonstrated little cytotoxicity.  We wish to more 
comprehensively study the family of PAMAM dendrimers as potential EPR passively 
targeted drug delivery vehicles for platinum-based drugs, thereby determining the optimal 
dendrimer size/generation and drug combination for in-depth preclinical evaluation.  
 
In this first study we have completed a systematic study of four anionic half-generation 
PAMAM dendrimers (G3.5-6.5) bound to the active component of cisplatin (cis-
{Pt(NH3)2}
2+
) to better evaluate this family of dendrimers as delivery vehicles for platinum 
drugs. The drug-dendrimer complexes were characterised by one dimensional and diffusion 
1
H NMR and inductively coupled plasma atomic emission spectrometry (ICP-AES) and drug 
release was monitored using guanosine monophosphate binding experiments. Finally, in vitro 
cytotoxicity was determined using the A2780, A2780cis and A2780cp cancer cell lines and in 
vivo cytotoxicity in an A2780 tumour xenograft. 
 
2. Experimental Section 
 
2.1. Materials 
  
Dendrimers were purchased from Dendritech or Sigma-Aldrich. Cisplatin, 3-
(diethylamino)propionate and 5-guanosine monophosphate were purchased from Sigma-
Aldrich. D2O (99.9%) was purchased from Cambridge Isotope Laboratories. All aqueous 
solutions were prepared using water filtered by a Millipore purification unit. Vivaspin™ 
columns used in centrifuge experiments were supplied by Sartorius Biolab or VWR. 
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2.2 NMR 
  
1
H NMR spectra were obtained on either a JEOL AS-400 or a Bruker AV-500 spectrometer 
and 
195
Pt spectra were recorded using a Bruker AV-400 spectrometer. All platinum 
containing samples were prepared as saturated solutions in 600 μL D2O and all other 
solutions prepared at various concentrations.  
1
H presaturation NMR spectra were recorded 
using 16-64 scans over a spectral width of 12 ppm with an irradiation offset value of 4.78 
ppm. 
195
Pt
 
spectra were recorded using 80,000 scans over a spectral width of 75,000 Hz and 
externally referenced to K2PtCl4 at -1631 ppm [24]. 
 
2.3 Diffusion NMR 
 
The diffusion coefficients of the free dendrimers and the drug-dendrimer complexes were 
determined using a standard Bruker diffusion ordered spectroscopy (DOSY) pulse sequence. 
Spectra were obtained using a Δ of 100 ms, a δ of 5 ms with 32 scans and a relaxation delay 
of 2 s. The diameters of the dendrimers were determined using the Stokes-Einstein equation: 
r
kT
D
6
  
where D is the diffusion coefficient (m
2
s
-1
), k is Boltzmann constant (J K
-1
), T is temperature 
(K), η is solvent viscosity (1.232 × 10-3 Pa s) and r is the hydrodynamic radius of the 
dendrimer (m). 
 
2.4 ICP-AES 
  
Analysis was carried out on a Thermo Electron X-Series II quadrupole ICP-AES with a Cetac 
ASX-520 autosampler. The instrument used a concentric nebuliser containing a Peltier cooled 
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conical single-pass spray chamber with impact bead and an integral peristaltic pump for 
sample uptake. A hexapole for CCT ED (Collision Cell Technology with Energy 
Discrimination) mode was used to remove polyatomic interferences. Instrumental operating 
conditions used were 1400W RF forward power, 13 L min
-1
 plasma flow, 1.0 L min
-1
 
nebulizer flow and 0.8 L min
-1
 auxiliary flow.  A sample flush time of 60 s, a wash time of 60 
s and a peak jump mode was used with a dwell time per isotope of 10 ms. Platinum 
concentration was determined using the 
194
Pt and 
195
Pt isotopes. The instrument 
was calibrated using solutions prepared from a Spex CertiPrep certified platinum standard 
diluted as required with 2% Fisher Primar Plus nitric acid. 
 
2.5 Cisplatin aquation 
 
Cisplatin was fully dissolved in water, wrapped in foil to prevent degradation by light before 
being stirring for 24 h with AgNO3 (2 mol. equiv.). The resultant AgCl precipitate was 
removed by filtration through a 0.2 µm nylon filter and the filtrate rotary evaporated to 
dryness. 
 
2.6. Synthesis of dendrimer-drug complexes 
 
Dendrimer in water (0.5-7.9 mM, 100-210 μL) was stirred with bis-aquated cisplatin (32-256 
mol. equiv.) overnight in water (10 mL). The solutions were then centrifuged in Vivaspin™ 
columns with a 5 kDa molecular weight cut-off membrane for 40 min at 3500 rpm. The drug-
dendrimer  complexes were collected separately into small sample vials and placed in a fume 
cupboard to evaporate the remaining water to yield a brown solid or instead diluted in 
H2O/D2O to a known concentration. The eluted water fractions from the bottom of the 
Page 8 of 30 
 
column were collected then evaporated to dryness and the residue reconstituted in water 
(10.00 mL) for analysis by ICP-AES.  
 
2.7. Monitoring drug release through binding to guanosine monophosphate 
 
The drug-dendrimer  complexes were dissolved in D2O (520 μL) and placed in an NMR tube. 
5′-guanosine monophosphate in D2O (2 mol. equiv. to total Pt content) was added and the 
solution heated for periods up to 1 week at temperatures up to 60 
o
C, and the 
1
H NMR spectra 
recorded at intervals.  
 
2.8. In vitro growth inhibition assays 
 
The A2780,  A2780cis and A2780cp ovarian cancer lines were grown in RPMI media 
containing 10% foetal calf serum, penicillin streptomycin and L-glutamate in a 5% CO2 
atmosphere. The cells were trypsinised, counted and adjusted to 500-1000 cells per well for 
the MTT stain assays and 2000 cells per well for the WST-1 stain assays (both in 96 well 
plates). Cisplatin, free dendrimer and drug-dendrimer  complex stock solutions were diluted 
with RPMI to prepare a dilution series based on the total platinum concentration (0.1 – 100 
μM). 10 μL aliquots were taken from these solutions and added in triplicate to each well 
along with RPMI only. The plate was then cultured for 24, 48, 72 or 96 h and 50 μL of WST-
1, followed by further incubation for 1 h. The absorbance of the WST-1 was measured using 
a plate reader at 450 nm, and the cells fixed with 4% paraformaldehyde with crystal violet 
used to stain the viable cells. The absorbance of the crystal violet stain was measured at 540 
nm. For assays using the MTT stain: on the final day MTT (50 L of a 5 mg mL-1 solution) 
was added to the 200 L of medium in each well and the plates were incubated at 37 oC for 4 
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h in the dark. Medium and MTT was then removed and the MTT-formazan crystals dissolved 
in 200 L DMSO. Glycine buffer (25 L per well, 0.1 M, pH 10.5) was added and the 
absorbance measured at 570 nm in a multiwell plate reader. 
 
2.9. In vivo tumour growth inhibition 
 
The human ovarian tumour cell line A2780 was used. These form well vascularised tumours 
that have a doubling time of about 3 days. Cells were injected subcutaneously into the right 
flank of female athymic nude mice. After about 10 days, once tumours had reached a mean 
diameter of at least 5 mm, mice were randomised into groups of 5. They were weighed and 
tumours measured by callipers daily. Mice were then treated (Day 0) with a single 
intraperitoneal injection of either phosphate buffered saline (control), cisplatin (6 mg/kg in 
phosphate buffered saline), cis-{Pt(NH3)2}-G6.5 dendrimer  complex (equivalent to 6 mg/kg 
cisplatin) or G6.5 dendrimer alone. Tumour volumes are calculated assuming spherical 
geometry and results are plotted as relative tumour volume or relative body weight. This 
method gives all weights and volumes a value of 1 on Day 0 and all other measurements are 
then related to the initial measurement. This was done because it is not possible to start with 
all tumours of equal size; however, the growth rate is consistent regardless of starting size 
provided it is greater than 5 mm. 
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3. Results and discussion 
 
3.1. Synthesis and characterisation of drug-dendrimer  complexes 
  
In order to attach the active component of cisplatin to the dendrimers, cisplatin needs to be 
aquated so that it can form reversible coordinate bonds to the carboxylate groups of the 
dendrimers (Fig. 1). Cisplatin can either be mono-aquated and form a single bond with the 
dendrimer or bis-aquated and form two bonds. We decided to use bis-aquated cisplatin as we 
hypothesised that this would increase the probability of platinum binding to the dendrimer 
and result in maximum retention of drug. 
 
Each different sized dendrimer was combined in unbuffered water with four equivalents (to 
the number of dendrimer surface groups) of triethylamine (TEA) and a half equivalent of bis-
aquated cisplatin (again, to the number of dendrimer surface groups). These solutions were 
then stirred for 5 h changing them from uncoloured to yellow coloured solutions. Whilst the 
pKa of the carboxylic acid groups of the dendrimer is around 2, the close packing of so many 
groups on such a small surface (64-512 carboxylic acid groups) makes complete 
deprotonation of all the carboxylates difficult. TEA, as a weak base, was added therefore to 
ensure the maximum number of carboxylate groups were available for coupling to the 
aquated cisplatin. The TEA as a weak nucleophile, however, can also potentially bind to the 
aquated cisplatin and in separate experiments of TEA and aquated cisplatin only, significant 
downfield shifts of the TEA resonances (0.26 ppm for the -CH2- group and 0.1 ppm for the –
CH3 group, respectively) indicate this is the case. Therefore, our method of coupling platinum 
to the dendrimers can form a range of platinum species; mostly dendrimer bound platinum 
but also TEA bound platinum. 
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Unbound aquated cisplatin, free TEA and platinum bound TEA were removed by 
centrifuging the samples on Vivaspin columns with a molecular weight cut off of 5 kDa, 
leaving the drug-dendrimer complexes in the top of the column (Fig. 1). The drug-dendrimer 
complexes are highly soluble in water, although if dried, they are difficult to get back into 
solution. As such, samples were generally diluted to a known concentration with either H2O 
or D2O immediately after centrifuge purification and kept until needed, rather than stored as a 
solid. 
 
The number of platinum molecules bound to each dendrimer was determined using ICP-AES. 
Originally we tried examining the drug-dendrimer complexes directly, but decomposition and 
deposition of the dendrimer in the machine blocked the ports and gave unreliable results. As 
such, the Vivaspin centrifuge filtrate (containing unbound aquated cisplatin, and TEA-bound-
platinum) was analysed to determine the concentration of unbound platinum, and from this, 
the amount of dendrimer bound platinum. Each dendrimer binds a different number of cis-
{Pt(NH3)2} molecules, consistent with the increasing number of carboxylate surface groups 
with increasing dendrimer generation (Table 1). Platinum binding efficiency decreases with 
increasing dendrimer size with 22 cis-{Pt(NH3)2} molecules for the G3.5 dendrimer 
representing binding of 68% of the theoretically available surface groups, increasing to 94 
cis-{Pt(NH3)2} molecules for the G6.5, which represents binding to only 37% of the available 
carboxylate groups. The lower binding efficiency of the higher generation dendrimers may be 
a function of the increased steric crowding of the surface groups making them less accessible 
to the platinum drug and/or the difficulty in deprotonating so many closely packed carboxylic 
acids.  
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Previously it has been shown that the inert DNA intercalating platinum complex, [Pt(5,6-
dimethyl-1,10-phenanthroline)(1S,2S-diaminocyclohexane)]
2+
 (56MESS) [25], which binds 
anionic PAMAM dendrimers solely through electrostatic interactions, was able to bind these 
dendrimers just as efficiently; 28 56MESS molecules for G3.5 to 96 56MESS molecules for 
G6.5 [15]. Our result is consistent with the results obtained for 56MESS, but significantly 
lower than the result obtained by Malik et al who found their cis-{Pt(NH3)2}-G3.5 dendrimer  
complex contained 24% w/w platinum by analysis, which represents as many as 57 cis-
{Pt(NH3)2} molecules per dendrimer [17]. No results for G4.5 or higher generation PAMAM 
dendrimers have previously been reported. 
 
The drug-dendrimer complexes were further characterised using one dimensional and 
diffusion 
1
H NMR spectroscopy. Each dendrimer, as provided by the manufacturer, shows 
two groups of resonances; one group of relatively high intensity peaks between 2.2 and 3.8 
ppm and a group of much smaller intensity between 5.6 and 6.2 ppm (Fig. 3). Upon 
centrifuging in a Vivaspin column the resonances around 5-6 ppm disappear leaving only a 
group of 9-10 resonances in the aliphatic region. These results indicate that the dendrimers, as 
supplied by Sigma-Aldrich and Dendritech, come with some lower molecular mass impurities 
that can be removed by Vivaspin centrifuge. Therefore, all commercial PAMAM dendrimers 
should be purified first before reaction with platinum drugs.  
 
Addition of bis-aquated cisplatin to each dendrimer induces changes in the dendrimer 
1
H 
NMR spectra (see Fig. 2). Five broad resonances are observed between 2.4 and 3.4 ppm, 
leaving three relatively sharps resonances at 2 and between 3.6 to 3.8 ppm. The size of the 
free dendrimers and the drug-dendrimer complexes was determined using diffusion NMR 
(see Table 1). The diffusion coefficient of the free dendrimers decreases with increasing 
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dendrimer generation, consistent with larger particle sizes [26]. The dendrimers range in 
diameter from 2.7 to 5.9 nm, which are significantly less than those previously reported [15]. 
Full generation PAMAM dendrimers G4-G7, have previously been shown to have diameters 
of 4-8 nm [27], and similar to the results reported by Wiwattanapatapee et al [28], for G3.5 
(4.0 nm) and G5.5 (6.7 nm) dendrimers, which are roughly in agreement with our results. In 
all cases, addition of cis-{Pt(NH3)2} results in a decrease in the size of each dendrimer. In 
their free form, the anionic carboxylate groups of the dendrimers most likely hydrogen bond 
with one or more shells of water molecules, thus greatly increasing the dendrimers’ effective 
hydrodynamic radius. When platinum binds to the dendrimers they become significantly less 
charged, and whilst the ammine groups of cis-{Pt(NH3)2} can still hydrogen bond with water, 
they may do so with much less efficiency, which may explain the reduction in dendrimer size 
upon platinum attachment. 
 
Whilst we used bis-aquated cisplatin, it wasn’t possible to determine whether the cis-
{Pt(NH3)2} binds to the dendrimers in a mono-dentate or bi-dentate fashion as no resonances 
are observed in the 
195
Pt NMR. This is presumably due to the incompatible tumbling rate of 
the drug-dendrimer  complex, which has been also been the case for other metal-based 
supracomplexes of PAMAM dendrimers [15]. 
 
3.2. Drug release and DNA binding 
 
To act as drug delivery vehicles it is important that the dendrimers are not only able to couple 
platinum drugs, but they must also be able to release the drugs so that they can bind to their 
cellular target, DNA. To do this we have examined platinum release from the dendrimers 
using 5΄-guanosine monophosphate binding experiments.  
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Each drug-dendrimer complex was incubated with two equivalents of 5-guanosine 
monophosphate (based on platinum concentration) in D2O and the solutions heated at 
temperatures up to 60 
o
C for periods of up to seven days. Platinum release from the 
dendrimers and binding to the guanosine monophosphate is observed through the downfield 
shift of the guanosine H8 resonance from 8.1 to 8.6 ppm (Fig. 3) [29]. Free cisplatin is known 
to react with guanosine/DNA in a relatively short time period (t1/2 = 0.5-4 h) [29-30]. For our 
drug-dendrimer complexes the platinum release is significantly slower and in fact never goes 
to theoretical completion (see Table 1). From the 
1
H NMR spectra it appears only a fraction 
of the bound cis-{Pt(NH3)2} is released from the dendrimer; G3.5, 18% of bound platinum; 
G4.5, 30%; G5.5, 35% and G6.5, 63%.  The reason for the lack of platinum release may be 
due to cis-{Pt(NH3)2} binding to the amine and amide groups within the dendrimer branches. 
Previously, Pellechia et al. demonstrated that K2PtCl4 when incubated with hydroxyl 
terminated, full generation G2 and G4 PAMAM dendrimers, the platinum formed a number 
of dendrimer adducts, including single (PtCl3N), double (PtCl2N2) and triple (PtClN3) amine 
adducts [18], and these are likely to also be formed by our aquated cisplatin.  
 
To examine if non-reversible amine binding is a probable explanation of the incomplete drug 
release from the dendrimer we examined the reaction of aquated cisplatin with 3-
(diethylamino)propionate by 
1
H NMR which we use as a representative “fragment” of a 
dendrimer arm (Fig. 4). This small molecule contains the functional groups of interest in the 
half-generation PAMAM dendrimers; a terminal carboxylate group separated from a tertiary 
amine by an ethyl chain. As purchased, the amine of the fragment is protonated. Upon 
addition of four equivalents of triethylamine (the same ratio used in the full dendrimer 
experiments), the four resonances of the fragment shift downfield by 0.24 to 0.65 ppm, which 
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is consistent with deprotonation of the amine. Incubation of the fragment with one equivalent 
of aquated cisplatin has an immediate effect, with selective upfield shifts of the fragment’s 
resonances. The two methyl groups closest to the amine shift by more than 0.2 ppm, whilst 
the resonance of the methyl protons closest to the carboxylate group only shifts 0.11 ppm. 
This  suggests coordination to the amine group rather than the carboxylate. The rapid binding 
of aquated cisplatin to the dendrimer fragment’s amine group is possibly a function of the 
group’s accessibility, which is why no binding to the carboxylate is observed. In the full 
dendrimer, where steric effects limit access to the amine groups, this binding would be 
expected to be slower. On further incubation of the fragment and aquated cisplatin at 37 
o
C 
for time periods of up to 48 hours, no further changes are observed, beyond those seen upon 
the immediate addition of the platinum.  
 
The results indicate that binding of the platinum atom to the tertiary amines in the full 
dendrimer arms is possible and may explain the incomplete drug release. What is likely to 
occur when the aquated cisplatin is coupled to the dendrimer is initial binding to a single 
carboxylate group.  Then, over time, it is likely that a 5-membered chelate ring is formed, 
involving a carboxylate oxygen and a tertiary amine nitrogen.  With longer time, the 
percentage of platinum bound to the amines will increase and there may even be formation of 
5-membered rings involving both the amine and amide  nitrogen atoms, and some cross-
linking of the dendrimer arms.   
 
Our guanosine monophosphate binding results demonstrate that the amount of platinum 
released is dependent on dendrimer generation; the higher the generation, the more platinum 
that is released. This may be due to the dense surface of higher generation dendrimers which 
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prevents access of the platinum atom to the internal amine/amide groups, thus ensuring a 
higher proportion of surface carboxylate attached drug molecules. 
 
The binding of platinum to the dendrimer amine/amide groups is problematic in that it will 
make synthesis of consistent drug-dendrimer complexes very difficult. If PAMAM 
dendrimers are used for drug delivery then our results suggest that higher generation 
dendrimers, >G5 are preferable to lower generation dendrimers <G4. Alternatively, the 
problem of amine binding might be overcome through the use of different dendrimer 
structures (i.e. not PAMAM dendrimers) that do not contain competitive binding sites for 
platinum. Instead, we hypothesise that other commercially available dendrimers could be 
functionalised with carboxylate groups through simple polyamide or click chemistry, and we 
plan to investigate this in the future.  
 
3.3. In Vitro Cytotoxicity 
 
The cytotoxicity of the free dendrimers and the drug-dendrimer complexes were determined 
in the human ovarian carcinoma cell line A2780 and its cisplatin-resistant daughter lines, 
A2780cis and A2780cp. These cell lines were chosen as ovarian tumours are known to easily 
developed acquired resistance and therefore in a particular need for a new drug delivery 
system to either increase the administered dose, thereby preventing the development of 
resistance, or to increase the delivered dose in already resistance tumours.  
 
Anionic half generation dendrimers have previously been shown to be significantly less 
cytotoxic compared with cationic full generation dendrimers [31], and our results 
demonstrated that the free PAMAM dendrimers have no cytotoxicity (IC50 >100 µM). 
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Because the release of platinum is so slow from the dendrimers, we incubated the cancer cell 
lines with drug-dendrimer complexes for time periods between 24 and 96 h. When the assays 
were conducted with the WST-1 stain in the A2780 and A2780cis lines, it was found the 
complexes were inactive, with IC50 values greater than 100 µM in all cases. Conversely, 
moderate cytotoxicity is observed when the A2780 and A2780cp lines are stained with MTT 
(Table 2), which indicates that WST-1 is not a suitable stain for in vitro screening of platinum 
drugs. Previously we have also shown that Alamar Blue is not a suitable stain for platinum 
drug screening [32], and we recommend the continued use of MTT. 
 
All four drug-dendrimer complexes display moderate activity in the A2780 cell line, although 
they are 2- to 11-fold less active than cisplatin. In the cisplatin-resistant line, all four 
complexes are significantly less cytotoxic and are not able to overcome resistance in the 
A2780cp line (as observed by larger resistance factors compared with normal cisplatin). The 
smaller dendrimer complexes (G3.5/4.5) are more active in the sensitive line than the larger 
dendrimers (G5.5/6.5) but conversely are also more cross-resistant. Within the margin of 
error both the G5.5 and G6.5 complexes are equally cytotoxic and cross-resistant in the two 
cell lines. 
 
3.5 In Vivo Effectiveness 
 
Whilst disappointing, the in vitro results were not surprising as previously Malik et al.[17] 
found that a PAMAM G3.5 dendrimer with the active component of cisplatin attached was 
almost inactive in CCRF, COR L23 and B16F10 cells when tested in vitro. Significant 
activity was only observed in vivo in L1210 murine leukaemia and B16 melanoma bearing 
mice.  In another study, in vitro cytotoxicity was only observed when a platinum-dendrimer  
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complex was incubated with cells for very long periods of time: 75 to 225 h [33]. Therefore 
our in vitro results do not necessarily imply that the drug-dendrimer complexes developed in 
this study are not active and different methods for determining cytotoxicity, including in vivo 
experiments, may be necessary for dendrimer-based delivery systems to be investigated 
properly.  
 
To this effect, and as only an initial pre-screen until other platinum drugs have been 
examined with PAMAM dendrimers, we then determined the effectiveness of the cis-
{Pt(NH3)2}-G6.5  complex in vivo using an A2780 tumour xenograft. The G6.5 complex was 
chosen because with the G5.5 complex, it was most effective at overcoming resistance. 
Additionally, it is able to release more cis-{Pt(NH3)2}  molecules than the other three 
dendrimers and because its larger size meant it was more likely to be trapped within the 
tumour vasculature compared with the other drug-dendrimer  complexes. 
 
When free cisplatin and the cis-{Pt(NH3)2}-G6.5 complex were administered at equimolar 
doses of 6 mg/kg (based on the number of releasable cisplatin molecules from the G6.5 
dendrimer), both demonstrated similar, and statistically significant, effectiveness in delaying 
tumour growth (Fig. 5). Conversely, the free G6.5 dendrimer had no effect on tumour growth 
(data not shown). When administered at a higher dose (8 mg/kg) the drug-dendrimer complex 
demonstrated similar systemic side-effects, as determined by the relative decrease in the 
mice’s body weight, but was significantly better at delaying tumour growth. Seven days after 
administration the tumour volumes of the cisplatin and drug-dendrimer complex (6 mg/kg) 
were 67 and 68%, respectively, of the tumour volume of the untreated control group (P 
<0.001). The drug-dendrimer complex (8 mg/kg) significantly delayed growth to an even 
greater extend with a tumour volume of only 55% compared to the control group (P <0.001). 
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The tumour doubling times were: control group 3.17 ± 0.15 days; cisplatin, 4.87 ± 0.14 days; 
drug-dendrimer 6 mg/kg 5.2 ± 0.35 days; and drug-dendrimer 8 mg/kg, 6.32 ± 0.37 days. 
These results further support our hypothesis that in vitro assays are not a suitable screen alone 
for platinum drug-nanoparticle delivery vehicle systems and in vivo experiments are required 
to determine their effectiveness properly. 
 
4. Conclusions 
In this paper we conducted a systematic examination of half generation anionic PAMAM 
dendrimers as delivery vehicles for the passive targeting of platinum drugs to solid tumours 
by the EPR effect. Bis-aquated cisplatin was dissolved in water with generation 3.5 to 6.5 
dendrimers and stirred for 5 h before being purified on Vivaspin centrifuge columns. The 
amount of platinum bound to the dendrimers increases with dendrimer size, although the 
binding efficiency decreases. Platinum release from the dendrimers was demonstrated using 
5΄-guanosine monophosphate binding experiments. Only a fraction of the dendrimer bound 
cis-{Pt(NH3)2} is released which may be a function of the drug forming non-reversible 
coordinate bonds to the amine and amide groups within the dendrimer branches. The drug-
dendrimer  complexes display moderate in vitro cytotoxicity in the A2780 and A2780cp cell 
lines, but effectiveness was only properly observed when examined in vivo using an A2780 
tumour xenograft. The drug-dendrimer complex displays a higher maximum tolerated dose 
compared with free cisplatin and is more active in vivo at a cisplatin equivalent dose of 8 
mg/kg. The results of our study demonstrate that half-generation PAMAM dendrimers may 
be effective for the delivery of platinum drugs. Further studies, however, need to include 
different methods for determining cytotoxicity beyond just in vitro growth inhibition assays 
and should include in vivo experiments, in order to evaluate fully the success of any 
nanoparticle-based drug delivery system. We next plan to examine the loading and binding of 
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other drugs to anionic PAMAM dendrimers, such as the active components of oxaliplatin, 
picoplatin and multinuclear platinum drugs (like BBR3464) to compare to cisplatin. When all 
these drugs have been evaluated we plan more in-depth biological screening, including 
determining quantitatively drug-dendrimer uptake both in vitro and in vivo, and the effect of 
the dendrimers on drug toxicity and effectiveness at multiple drug doses and in different 
tumour xenografts. 
 
5. Abbreviations 
cisplatin cis-diamminedichloridoplatinum(II) 
DOSY  diffusion order spectroscopy 
EPR  enhanced permeability and retention 
G  dendrimer generation (size) 
ICP-AES inductively coupled plasma atomic emission spectroscopy 
IP  intraperitoneal 
IC50  the required in vitro concentration required to inhibition cell growth by 50% 
MTT  (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
PAMAM poly(amidoamine) 
Rf  resistance factor 
TEA  triethylamine 
WST  water soluble tetrazolium salt 
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Table 1. Binding and release characteristics of the active component of cis-{Pt(NH3)2} to the anionic half generation PAMAM dendrimers G3.5 
to 6.5. 
 
Generation No of surface groups 
(Theoretical binding sites)
a 
No. of bound  
Pt molecules 
(% efficacy)
b 
No. of releasable 
Pt molecules 
(% efficacy)
c 
Particle size 
D (10-10 m2s-1)d Diameter (nm) 
Free Bound Free Bound 
3.5 64 (32) 22 (68%) 4 (18%) 1.30 2.15 2.74 1.66 
4.5 128 (64) 37 (58%) 11 (30%) 0.91 1.12 3.91 3.17 
5.5 256 (128) 54 (42%) 19 (35%) 0.66 1.06 5.44 3.37 
6.5 512 (256) 94 (37%) 59 (63%) 0.60 0.89 5.93 4.01 
a. Number of binding sites assumes platinum binding to the dendrimer is in a bidentate manner. b. Percentage of platinum molecules as a 
function of total bidentate binding sites. c. Release efficiency is the percentage of platinum molecules released as a function of total bound cis-
{Pt(NH3)2}. d. Diffusion coefficient of the dendrimer.
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Table 2. The in vitro cytotoxicity of the drug-dendrimer complexes in the human ovarian 1 
cancer cell line A2780 and its cisplatin resistant daughter line A2780cp. 2 
 3 
Drug/complex 
IC50 (µM)
a
 Resistance factor 
(Rf)
b 
A2780 A2780cp 
cisplatin 0.14 ± 0.01 1.90 ± 0.37 13.6 
cis-{Pt(NH3)2}-G3.5 0.40 ± 0.07 24.5 ± 4.4 61.3 
cis-{Pt(NH3)2}-G4.5 0.62 ± 0.05 18.8 ± 1.0 30.3 
cis-{Pt(NH3)2}-G5.5 1.48 ± 0.20 26.8 ± 0.6 18.1 
cis-{Pt(NH3)2}-G6.5 1.07  ± 0.38 25.2 ± 1.7 23.6 
a. Based on the total “releasable” platinum concentration per mole of dendrimer. b. Defined 4 
as the IC50 value in the resistant line divided by the IC50 value in the sensitive line; the lower 5 
the Rf the better the complex is at overcoming resistance.6 
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 7 
Fig. 1. The chemical structure of a generation 2.5 PAMAM dendrimer (showing only one 8 
hemisphere of the polymer), and the aquation and subsequent attachment of the active 9 
component of cisplatin to the dendrimers. 10 
11 
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 12 
 13 
Fig. 2.  The 
1
H NMR spectra (400 MHz, D2O) of (a) unpurified G4.5 dendrimer, (b) G4.5 14 
dendrimer purified on a Vivaspin column with a 5 kDa filtration membrane and (c) purified 15 
G4.5 cis-{Pt(NH3)2}dendrimer  complex. 16 
 17 
18 
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 19 
Fig. 3. The 
1
H NMR spectra of the G4.5 drug-dendrimer  complex and 5΄-guanosine 20 
monophosphate in unbuffered D2O at (a) 0 hours and (b) after 7 days, showing the large 21 
downfield shift of the guanosine H8 resonance upon binding by cis-{Pt(NH3)2} (8.1→8.7 22 
ppm) as it is released from the dendrimer. 23 
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 24 
Fig. 4. The chemical structure of 3-(diethylamino)propionate which contains the two key 25 
functional groups of the dendrimer arms, a tertiary amine and a carboxylic acid/carboxylate, 26 
which we used as a representation of a dendrimer fragment.27 
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 28 
 29 
Fig. 5. (Top) Effect of control (●, saline), cisplatin (○, 6 mg/kg), cis-{Pt(NH3)2}-G6.5  30 
complex (▼, 6 mg/kg) and cis-{Pt(NH3)2}-G6.5  complex (Δ, 8 mg/kg equivalent) on the 31 
growth of an A2780 ovarian tumour xenograft after a single IP administration on day 0. 32 
(Bottom) The loss of body weight of the mice after a single IP injection of saline or drug, 33 
demonstrating the similar systemic toxic effect of the drugs. 34 
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